609 related articles for article (PubMed ID: 31018667)
21. Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.
Yao Y; Tang XF; Zhang JH; He C; Ma YL; Xu JJ; Song Y; Liu R; Meng XM; Song L; Chen J; Wang M; Xu B; Gao RL; Yuan JQ
Thromb Res; 2016 May; 141():28-34. PubMed ID: 26962983
[TBL] [Abstract][Full Text] [Related]
22. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
[TBL] [Abstract][Full Text] [Related]
23. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
[TBL] [Abstract][Full Text] [Related]
24. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
[TBL] [Abstract][Full Text] [Related]
25. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP; Backman JD; Reny JL; Bergmeijer TO; Mitchell BD; Ritchie MD; Déry JP; Pakyz RE; Gong L; Ryan K; Kim EY; Aradi D; Fernandez-Cadenas I; Lee MTM; Whaley RM; Montaner J; Gensini GF; Cleator JH; Chang K; Holmvang L; Hochholzer W; Roden DM; Winter S; Altman RB; Alexopoulos D; Kim HS; Gawaz M; Bliden KP; Valgimigli M; Marcucci R; Campo G; Schaeffeler E; Dridi NP; Wen MS; Shin JG; Fontana P; Giusti B; Geisler T; Kubo M; Trenk D; Siller-Matula JM; Ten Berg JM; Gurbel PA; Schwab M; Klein TE; Shuldiner AR;
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):203-210. PubMed ID: 31504375
[TBL] [Abstract][Full Text] [Related]
27. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
28. Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.
Zhang S; Zhu J; Li H; Wang L; Niu J; Zhu B; He L; Shen L; Qin S; Fang S
Cardiology; 2018; 140(1):21-29. PubMed ID: 29635252
[TBL] [Abstract][Full Text] [Related]
29. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
Giustino G; Redfors B; Kirtane AJ; Mehran R; Dangas GD; Witzenbichler B; Neumann FJ; Weisz G; Généreux P; Maehara A; McAndrew T; Farhan S; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Gurbel P; Ben-Yehuda O; Stone GW
JACC Cardiovasc Interv; 2018 Jul; 11(13):1277-1286. PubMed ID: 29908967
[TBL] [Abstract][Full Text] [Related]
30. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
[TBL] [Abstract][Full Text] [Related]
31. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
[TBL] [Abstract][Full Text] [Related]
32. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study.
Mahla E; Metzler H; Bornemann-Cimenti H; Prueller F; Raggam RB; Pregartner G; Berghold A; Baumann A; Goeroeg C; Gurbel PA
Thromb Haemost; 2018 May; 118(5):864-872. PubMed ID: 29625498
[TBL] [Abstract][Full Text] [Related]
33. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
[TBL] [Abstract][Full Text] [Related]
34. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Xu K; Liu X; Li Y; Wang Y; Zang H; Guo L; Wang Y; Zhao W; Wang X; Han Y
Cardiovasc Ther; 2016 Oct; 34(5):337-42. PubMed ID: 27328023
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
[TBL] [Abstract][Full Text] [Related]
37. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
[TBL] [Abstract][Full Text] [Related]
38. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
39. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
40. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
